These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31081077)

  • 1. LINC01308 accelerates the malignant progression of ovarian cancer by binding to miRNA-506.
    Zhang YY; Li P; Zhu MZ; Guo Y; Yang J
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3253-3260. PubMed ID: 31081077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.
    Sun D; Fan XH
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2345-2352. PubMed ID: 30964158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiRNA-96 accelerates the malignant progression of ovarian cancer via targeting FOXO3a.
    Yang N; Zhang Q; Bi XJ
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):65-73. PubMed ID: 31957819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lnc00908 promotes the development of ovarian cancer by regulating microRNA-495-5p.
    Jiang JN; Hong QY; Gao HJ; Lai BL; Lan JF; Yang Q
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1388-1396. PubMed ID: 30840259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1.
    Pei CL; Fei KL; Yuan XY; Gong XJ
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10657-10663. PubMed ID: 31858532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA GIHCG promotes development of ovarian cancer by regulating microRNA-429.
    Yao N; Yu L; Zhu B; Gan HY; Guo BQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8127-8134. PubMed ID: 30556850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating KLF4.
    Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
    Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA MIF-AS1 aggravates the progression of ovarian cancer by sponging miRNA-31-5p.
    Fan Y; Wang L; Han XC; Ma HY; Zhang N; Zhe L
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2248-2255. PubMed ID: 32196575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer.
    Zheng W; Tian X; Cai L; Shen YM; Cao QS; Yang JY; Tian GY
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10443-10452. PubMed ID: 31841198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144.
    Sheng M; Wei N; Yang HY; Yan M; Zhao QX; Jing LJ
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7283-7294. PubMed ID: 31539115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA PVT1 promotes cell proliferation and invasion through regulating miR-133a in ovarian cancer.
    Yang Q; Yu Y; Sun Z; Pan Y
    Biomed Pharmacother; 2018 Oct; 106():61-67. PubMed ID: 29957467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186.
    Luo X; Song Y; Tang L; Sun DH; Ji DG
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7788-7797. PubMed ID: 30536320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA HANR aggravates the progression of non-small cell lung cancer via mediating miRNA-140-5p.
    Li SJ; Wu YX; Liang YH; Gao Y; Wu AB; Zheng HY; Yang ZX
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):704-711. PubMed ID: 32016972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression.
    Zheng J; Zhou Y; Li XJ; Hu JM
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6839-6848. PubMed ID: 31486483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.
    Zheng SN; Ge DW; Tang J; Yang J; Yan JW; Qiu JJ; Yin ZW; Ni Y; Zhao L; Chen X; Yang L
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(1):96-104. PubMed ID: 30657551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of LncRNA FOXC2-AC1 promoting lung cancer metastasis by regulating miR-107.
    Wu XF; Lu JT; Chen W; Wang N; Meng JC; Zhou YH
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):690-698. PubMed ID: 30720176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CircRNA_MYLK promotes malignant progression of ovarian cancer through regulating microRNA-652.
    Zhao Y; Hu Y; Shen Q; Chen Q; Zhu XJ; Jiang SS; Zhang Q
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5281-5291. PubMed ID: 32495861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.
    Zhang L; Wang YH; Wang L
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(14):6062-6069. PubMed ID: 31364107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiRNA-199 inhibits malignant progression of lung cancer through mediating RGS17.
    Su WZ; Ren LF
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3390-3400. PubMed ID: 31081094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA DLEU1 accelerates the malignant progression of clear cell renal cell carcinoma via regulating miRNA-194-5p.
    He GZ; Yu SY; Zhou QP; Chen ML; Zhang YW; Zheng Y; Zhang ZB; Han ZY; Yu J
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10691-10698. PubMed ID: 31858537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.